Please login to the form below

Not currently logged in
Email:
Password:

RNA

This page shows the latest RNA news and features for those working in and with pharma, biotech and healthcare.

Horizon taps academic partner to boost gene editing platform

Horizon taps academic partner to boost gene editing platform

Unlike CRISPR however, base editing utilises a nuclease-deficient CRISPR protein and an RNA-based recruitment mechanism to guide a non-nuclease DNA modifying enzyme to the disease-causing gene.

Latest news

More from news
Approximately 4 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    It’s made up of two components, a synthetically produced guide RNA (gRNA) and an enzyme – usually CRISPR- associated endonuclease protein (Cas9) – both of which form a ribonucleoprotein (RNP) complex.

  • Deal Watch October 2018

    Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Pipeline and evolution of the RNAi platform. Analysts are agreed that RNA-based therapeutics could, in the long term, revolutionise how many diseases are treated, and Alnylam’s leadership in the

  • Pharma deals continue to slide Pharma deals continue to slide

    32.5. Ethris (DE). AstraZeneca (GB). R&D collaboration option to license. Stabilised non-immunogenic modified RNA technology for respiratory diseases.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    But ultimately deals will continue in a diverse range of therapeutic entities as technological improvements appear to be bearing fruit in areas such as gene therapy and RNA-based therapeutics.

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. ... As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors.

  • MIT chief financial officer joins Moderna Therapeutics MIT chief financial officer joins Moderna Therapeutics

    We look forward to leveraging Israel's insights as Moderna evolves into a leading, clinical stage biotechnology company by harnessing the promise of messenger RNA science to improve lives.”.

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics